Cargando…
Potential Pharmacokinetic Drug–Drug Interaction Between Harmine, a Cholinesterase Inhibitor, and Memantine, a Non-Competitive N-Methyl-d-Aspartate Receptor Antagonist
Harmine (HAR) is a beta-carboline alkaloid widely distributed in nature. It exhibits psychopharmacological effects of improving learning and memory. However, excessive dose of HAR can cause central tremor toxicity, which may be related to the glutamate system. Memantine (MEM) is a non-competitive N-...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6479946/ https://www.ncbi.nlm.nih.gov/pubmed/30978991 http://dx.doi.org/10.3390/molecules24071430 |
_version_ | 1783413462624370688 |
---|---|
author | Zhang, Yunpeng Li, Shuping Wang, Youxu Deng, Gang Cao, Ning Wu, Chao Ding, Wenzheng Wang, Yuwen Cheng, Xuemei Wang, Changhong |
author_facet | Zhang, Yunpeng Li, Shuping Wang, Youxu Deng, Gang Cao, Ning Wu, Chao Ding, Wenzheng Wang, Yuwen Cheng, Xuemei Wang, Changhong |
author_sort | Zhang, Yunpeng |
collection | PubMed |
description | Harmine (HAR) is a beta-carboline alkaloid widely distributed in nature. It exhibits psychopharmacological effects of improving learning and memory. However, excessive dose of HAR can cause central tremor toxicity, which may be related to the glutamate system. Memantine (MEM) is a non-competitive N-methyl-d-aspartate receptor antagonist. It can be used for the treatment of Alzheimer’s disease and also can block the neurotoxicity caused by glutamate. Therefore, combination of HAR and MEM would be meaningful and the pharmacokinetics investigation of HAR and MEM in combination is necessary. A ultra-performance liquid chromatography tandem mass spectrometry (UPLC-MS/MS) method was established and validated for the simultaneous quantitative determination of MEM, HAR and harmol (HOL), a main metabolite of HAR, in rat plasma after oral administration of HAR and MEM in combination (5.0 mg/kg of MEM combined with 20.0, 40.0, 80.0 mg/kg of HAR). The contents of HAR and HOL were determined after oral administration of HAR (20.0, 40.0 and 80.0 mg/kg), and the content of MEM was determined after oral administration of MEM (5.0 mg/kg). Blood samples were collected from each rat at 0 (pre-dose), 0.08, 0.17, 0.25, 0.33, 0.50, 0.75, 1.0, 2.0, 4.0, 8.0, 12.0 and 24.0 h after administration. The maximum peak concentration (C(max)) of MEM was obviously decreased, and the area under the plasma concentration versus time curve from zero to time t (AUC((0-t))) and mean residence time (MRT) were significantly increased after combination with HAR. The C(max) and AUC((0-t)) of HAR and its metabolite HOL were increased after combination with MEM. These findings suggested that co-administration of HAR and MEM could extend their residence time in rats, and then might increase the efficacy for treatment of Alzheimer’s disease. Therefore, this study will provide a basis for the rational combined application of HAR and MEM. |
format | Online Article Text |
id | pubmed-6479946 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-64799462019-04-30 Potential Pharmacokinetic Drug–Drug Interaction Between Harmine, a Cholinesterase Inhibitor, and Memantine, a Non-Competitive N-Methyl-d-Aspartate Receptor Antagonist Zhang, Yunpeng Li, Shuping Wang, Youxu Deng, Gang Cao, Ning Wu, Chao Ding, Wenzheng Wang, Yuwen Cheng, Xuemei Wang, Changhong Molecules Article Harmine (HAR) is a beta-carboline alkaloid widely distributed in nature. It exhibits psychopharmacological effects of improving learning and memory. However, excessive dose of HAR can cause central tremor toxicity, which may be related to the glutamate system. Memantine (MEM) is a non-competitive N-methyl-d-aspartate receptor antagonist. It can be used for the treatment of Alzheimer’s disease and also can block the neurotoxicity caused by glutamate. Therefore, combination of HAR and MEM would be meaningful and the pharmacokinetics investigation of HAR and MEM in combination is necessary. A ultra-performance liquid chromatography tandem mass spectrometry (UPLC-MS/MS) method was established and validated for the simultaneous quantitative determination of MEM, HAR and harmol (HOL), a main metabolite of HAR, in rat plasma after oral administration of HAR and MEM in combination (5.0 mg/kg of MEM combined with 20.0, 40.0, 80.0 mg/kg of HAR). The contents of HAR and HOL were determined after oral administration of HAR (20.0, 40.0 and 80.0 mg/kg), and the content of MEM was determined after oral administration of MEM (5.0 mg/kg). Blood samples were collected from each rat at 0 (pre-dose), 0.08, 0.17, 0.25, 0.33, 0.50, 0.75, 1.0, 2.0, 4.0, 8.0, 12.0 and 24.0 h after administration. The maximum peak concentration (C(max)) of MEM was obviously decreased, and the area under the plasma concentration versus time curve from zero to time t (AUC((0-t))) and mean residence time (MRT) were significantly increased after combination with HAR. The C(max) and AUC((0-t)) of HAR and its metabolite HOL were increased after combination with MEM. These findings suggested that co-administration of HAR and MEM could extend their residence time in rats, and then might increase the efficacy for treatment of Alzheimer’s disease. Therefore, this study will provide a basis for the rational combined application of HAR and MEM. MDPI 2019-04-11 /pmc/articles/PMC6479946/ /pubmed/30978991 http://dx.doi.org/10.3390/molecules24071430 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Zhang, Yunpeng Li, Shuping Wang, Youxu Deng, Gang Cao, Ning Wu, Chao Ding, Wenzheng Wang, Yuwen Cheng, Xuemei Wang, Changhong Potential Pharmacokinetic Drug–Drug Interaction Between Harmine, a Cholinesterase Inhibitor, and Memantine, a Non-Competitive N-Methyl-d-Aspartate Receptor Antagonist |
title | Potential Pharmacokinetic Drug–Drug Interaction Between Harmine, a Cholinesterase Inhibitor, and Memantine, a Non-Competitive N-Methyl-d-Aspartate Receptor Antagonist |
title_full | Potential Pharmacokinetic Drug–Drug Interaction Between Harmine, a Cholinesterase Inhibitor, and Memantine, a Non-Competitive N-Methyl-d-Aspartate Receptor Antagonist |
title_fullStr | Potential Pharmacokinetic Drug–Drug Interaction Between Harmine, a Cholinesterase Inhibitor, and Memantine, a Non-Competitive N-Methyl-d-Aspartate Receptor Antagonist |
title_full_unstemmed | Potential Pharmacokinetic Drug–Drug Interaction Between Harmine, a Cholinesterase Inhibitor, and Memantine, a Non-Competitive N-Methyl-d-Aspartate Receptor Antagonist |
title_short | Potential Pharmacokinetic Drug–Drug Interaction Between Harmine, a Cholinesterase Inhibitor, and Memantine, a Non-Competitive N-Methyl-d-Aspartate Receptor Antagonist |
title_sort | potential pharmacokinetic drug–drug interaction between harmine, a cholinesterase inhibitor, and memantine, a non-competitive n-methyl-d-aspartate receptor antagonist |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6479946/ https://www.ncbi.nlm.nih.gov/pubmed/30978991 http://dx.doi.org/10.3390/molecules24071430 |
work_keys_str_mv | AT zhangyunpeng potentialpharmacokineticdrugdruginteractionbetweenharmineacholinesteraseinhibitorandmemantineanoncompetitivenmethyldaspartatereceptorantagonist AT lishuping potentialpharmacokineticdrugdruginteractionbetweenharmineacholinesteraseinhibitorandmemantineanoncompetitivenmethyldaspartatereceptorantagonist AT wangyouxu potentialpharmacokineticdrugdruginteractionbetweenharmineacholinesteraseinhibitorandmemantineanoncompetitivenmethyldaspartatereceptorantagonist AT denggang potentialpharmacokineticdrugdruginteractionbetweenharmineacholinesteraseinhibitorandmemantineanoncompetitivenmethyldaspartatereceptorantagonist AT caoning potentialpharmacokineticdrugdruginteractionbetweenharmineacholinesteraseinhibitorandmemantineanoncompetitivenmethyldaspartatereceptorantagonist AT wuchao potentialpharmacokineticdrugdruginteractionbetweenharmineacholinesteraseinhibitorandmemantineanoncompetitivenmethyldaspartatereceptorantagonist AT dingwenzheng potentialpharmacokineticdrugdruginteractionbetweenharmineacholinesteraseinhibitorandmemantineanoncompetitivenmethyldaspartatereceptorantagonist AT wangyuwen potentialpharmacokineticdrugdruginteractionbetweenharmineacholinesteraseinhibitorandmemantineanoncompetitivenmethyldaspartatereceptorantagonist AT chengxuemei potentialpharmacokineticdrugdruginteractionbetweenharmineacholinesteraseinhibitorandmemantineanoncompetitivenmethyldaspartatereceptorantagonist AT wangchanghong potentialpharmacokineticdrugdruginteractionbetweenharmineacholinesteraseinhibitorandmemantineanoncompetitivenmethyldaspartatereceptorantagonist |